Published on December 8, 2009 at 6:11 AM
AbSorber has received patent protection for its transplantation cross
match-test XM-ONE® in the European countries. The patent was previously
approved in New Zealand which was the first country to approve a patent
for AbSorbers product. The European countries are highly prioritized
markets for AbSorber and the patent approval is an important milestone
in Absorbers intellectual property strategy.
The patent was granted by the European Patent Office (EPO) and AbSorber
has also patent applications pending for XM-ONE® in the US, Japan and
other key transplantation markets. The company expects more countries to
follow the European approval of the XM-ONE® patent.
XM-ONE® is unique in that it is the first standardized test that can
detect antibodies against the cells that line the inside of blood
vessels. These endothelial cells are the first point of contact between
the transplanted organ and the recipient’s immune system.
Anti-endothelial cell antibodies have been shown to play a key role in
causing post-transplantation rejections.
http://www.absorber.se/